📰 Multiple Ascending Dose Study News
Multiple Ascending Dose Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple Ascending Dose Study. Real-time updates on events, politics, business and more.
March 27, 2024
TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and
May 19, 2023
Structure Therapeutics announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference.
May 11, 2023
- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., May 11, 2023 -- Dyne... | May 11, 2023
December 1, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor...
August 2, 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / August 2, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule
August 2, 2022
Press release content from Accesswire. The AP news staff was not involved in its creation.
July 5, 2022
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on clinical study data with its leading drug ...
July 5, 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / July 5, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule